KB004 : A Phase I Safety and Bioimaging Trial of KB004 in Patients With Glioblastoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal
Cancers

Systemic therapy | Brain and spinal cordBrain,Glioblastoma (GBM) ,Glioma

Trial Overview Read MoreRead more

This phase I trial is testing a new drug (KB004) in patients with recurrent glioblastoma.
 

This trial is treating patients with glioblastoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I Safety and Bioimaging Trial of KB004 in Patients With Glioblastoma

Other Non-Commercial Sponsor

Olivia Newton-John Cancer Research Institute

Summary

Participants in this trial will be entered at each KB004 dose level sequentially until 3-6 patients are evaluable for safety. Three sequential cohorts are planned: 3.5mg/kg, 5.25 mg/kg and 7.9 mg/kg

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next